The famous investor Cathie Wood is renowned for choosing companies focused on disruptive innovation, meaning companies that have the potential to change how industries work over the long term. So when ...

Tempus AI, Inc. (NASDAQ:TEM) is one of the best Nancy Pelosi Stocks to buy in 2026. On January 27, Tempus AI, Inc. (NASDAQ:TEM) confirmed that its Immune Profile Score Test accurately predicts patient ...

Healthcare leaders are partnering with Tempus AI to bolster their development pipelines. Tempus' sales are expanding at a rapid pace. Tempus expects revenue to grow 83% year over year to $367 million ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full ...

I'm David Westenberg, the life science tools and diagnostics analyst at Piper. With me today is Tempus AI. I'm happy to have the CFO, Jim Rogers. Liz is in the audience as well, if anyone -- any ...

Tempus AI specializes in developing artificial intelligence solutions to improve patient outcomes in various healthcare fields. Ark Invest reduced the Tempus AI position in the ARK Innovation ETF.

Great news for Tempus AI stock! The company has just received FDA approval for an upgraded version of its Tempus Pixel platform — a cardiac imaging system that uses advanced AI to deliver highly ...

NEW YORK – With its recently announced acquisition of digital pathology firm Paige, Tempus AI is broadening its offerings and expanding to a new market. The $81.3 million deal, announced last week, ...

Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Friday after acquiring Paige, an AI company specializing in digital pathology. Tempus is a technology company focused on adopting AI to advance ...

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial-intelligence-powered programs for spotting the signs of cancer. The deal totals $81.25 million, ...

Paige’s strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc ...